May 22, 2019
Exicure to Present at TIDES 2019 on Preclinical and Clinical Development of AST-008
Exicure to Present at TIDES 2019 on Preclinical and Clinical Development of AST-008
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
May 21, 2019
Columbia Care and Westmed testing precisely formulated cannabis-based drugs can relieve pain from arthritis
Columbia Care and Westmed testing precisely formulated cannabis-based drugs can relieve pain from arthritis
May 21, 2019
Seattle Genetics appoints new Chief Commercial Officer
Seattle Genetics has announced the appointment ofRobin G. Taylor, M.B.A., Ph.D., as Chief Commercial Officer
May 21, 2019
AmerisourceBergen’s Xcenda acquires Dymaxium
Xcenda,a part of AmerisourceBergen, today announced the acquisition ofDymaxium, a trusted market access partner specializing in the exchangeof evidence and information between payers and life science companiesthrough its FormularyDecisions.com® platform.
May 21, 2019
Debiopharm enrolls patient to test treatment in solid tumors
Debiopharm has enrolled first patient in SMARTPLUS-106, a Phase lb/II study in patients failing prior PD-1/PD-L1 treatment in selected solid tumors.
May 21, 2019
Design contract for UK’s first Vaccines Manufacturing Innovation Centre won by WHP
The development of the UK’s first dedicated Vaccines Manufacturing Innovation Centre (VMIC) has moved a step closer with the contract to design an advanced array of laboratory and production facilities within a ‘cleanroom wrap’ environment being awarded to WHP, the company has said in a statement.
May 21, 2019
US Breast Cancer Drug Market 2019-2025 Opportunity: $ 20 Billion
DUBLIN–(BUSINESS WIRE)–The “US Breast Cancer Drug Market, Price, Dosage & Clinical Pipeline Insight 2025” drug pipelines has been added to…
May 20, 2019
PharmaCyte Biotech Proceeding with GMP Production of Pancreatic Cancer Product After Successful Changes to Manufacturing Process
PharmaCyte Biotech Proceeding with GMP Production of Pancreatic Cancer Product After Successful Changes to Manufacturing Process
May 20, 2019
Merck Keytruda in triple-negative breast cancer (TNBC) study misses its pre-specified primary endpoint of superioroverall survival (OS) compared to chemotherapy
The KEYTRUDA breast cancer clinical development program encompassesseveral internal and external collaborative studies, including threeongoing registration-enabling studies in TNBC.
May 20, 2019
Clovis Oncology’s Rubraca Rubraca passes over placebo from a patient perspective in Advanced Ovarian Cancer
Quality-adjusted progression free survival (QA-PFS) andquality-adjusted time without cancer related symptoms or toxicity(Q-TWiST) demonstrate the benefit of Rubraca maintenance treatment overplacebo from a patient perspective